Hyperfine (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.
How this was made
The 30-second read
Why it matters
Traders can update models for FY2026 revenue, gross margin, and cash burn, and reassess the probability-weighted timeline for contrast labeling and reimbursement expansion based on the stated FDA submission target and study performance metrics.
Market read
Fresh quarterly results and explicit FY2026 guidance ranges, plus a concrete contrast-labeling FDA submission target by end of 2026, are the main catalysts for repricing expectations.
What to watch
Placement timing and customer purchasing cycles are explicitly flagged as a driver of quarter-to-quarter revenue variability, which can increase near-term earnings volatility even with improving margins.
Background
The article is a transcript-style summary of Hyperfine’s Q2 2026 earnings call, covering financial results, guidance, cash runway, and clinical/commercial progress for its Swoop portable MRI systems.
Ticker impact
Hyperfine reported Q2 2026 revenue of $3.9M (+45% YoY) and guided FY2026 revenue to $20M-$22M with gross margin 50%-55%.
Likely positive bias if investors focus on accelerating adoption, sustained 50%+ gross margins, and extended runway into 2028; downside risk if burn/guidance or regulatory timing disappoints.
The article includes multiple new, decision-relevant disclosures: quarterly financials, full-year guidance ranges, cash runway extension, and specific clinical timing (contrast labeling FDA submission by end of 2026) that affect expectations for reimbursement and utilization.
Market effects
Portable MRI and imaging-device peers may see read-across on reimbursement potential if contrast labeling and CPT pathways progress as guided.
International placements (Europe/other) highlight demand outside the US, potentially influencing sentiment toward non-US commercialization for imaging platforms.
FDA labeling expansion and clinical performance metrics can affect global adoption expectations for portable MRI workflows.
Counterpoint
Despite strong growth, the company still reports a sizable net loss and relies on financing (ATM proceeds), so the market may discount guidance until profitability or durable reimbursement traction is proven.
Key entities
- companyHyperfine, Inc.
Portable MRI developer reporting Q2 2026 results, FY2026 guidance, cash runway extension, and clinical milestones for Swoop (Model 2) including contrast labeling plans.
- executiveMaria Sainz
CEO who discussed mainstream adoption progress, scan volume, and contrast labeling reimbursement rationale.
- executiveBrett Hale
CFO who provided financial commentary and highlighted revenue timing risks tied to purchasing cycles and mix.
